Take part in an investigational gene therapy trial for people living with ALS.
Take part in an investigational gene therapy trial for people living with ALS.
The main goal of this study is to find the right dose of investigational compound INS1202 and evaluate if it is safe and tolerable when given as a single injection into the spinal fluid.
We are looking at how the investigational compound INS1202 works in the body. This clinical study is for people aged 18 to 79 who have ALS, a disease affecting nerve cells, and either have a specific genetic change called SOD1 mutation or do not have any known genetic changes related to ALS. This study is being sponsored by Insmed Gene Therapy, LLC.
To learn more about the ARMOR study,
please contact Insmed Medical Information
To participate in this ALS research study, you must meet these and other criteria that may apply:
18 to 79 years of age (both inclusive)
Diagnosed with amyotrophic lateral sclerosis (ALS) with or without SOD1 mutations
Symptomatic ALS with disease duration less than or equal to 42 months
Corticosteroids will be dispensed and taken
daily for approximately 8 weeks and eventually tapered off.
Negative testing for known mutations
associated with familial ALS
To participate in this study, you must meet these and other criteria that may apply:
Diagnosed with amyotrophic lateral sclerosis (ALS) with or without SOD1 mutations
Corticosteroids will be dispensed and taken
daily for approximately 8 weeks and eventually tapered off.
This ALS trial is open and recruiting.
Find eligibility requirements, study locations, and contact details — all in one place.
